| 000 | 01270 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250513124607.0 | ||
| 264 | 0 | _c19970929 | |
| 008 | 199709s 0 0 eng d | ||
| 022 | _a1368-4736 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAbdul-Ahad, A K | |
| 245 | 0 | 0 |
_aIncidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. _h[electronic resource] |
| 260 |
_bCytokines, cellular & molecular therapy _cMar 1997 |
||
| 300 |
_a27-32 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aAntibody Formation |
| 650 | 0 | 4 | _aCHO Cells |
| 650 | 0 | 4 | _aClinical Protocols |
| 650 | 0 | 4 | _aCricetinae |
| 650 | 0 | 4 | _aCross Reactions |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEscherichia coli _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-beta _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNeutralization Tests |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadverse effects |
| 700 | 1 | _aGalazka, A R | |
| 700 | 1 | _aRevel, M | |
| 700 | 1 | _aBiffoni, M | |
| 700 | 1 | _aBorden, E C | |
| 773 | 0 |
_tCytokines, cellular & molecular therapy _gvol. 3 _gno. 1 _gp. 27-32 |
|
| 999 |
_c9266101 _d9266101 |
||